Jump to section
To reach the holy grail of continuous, non-invasive, and medical-grade multi-biomarker monitoring, in a next-generation wearable, providing us with data to live longer, healthier lives.
For many in the healthcare space, it has been determined that personalised medical care is the next step in improving patient outcomes around the globe. Liom (previously Spiden) is looking to be a part of this next generation of healthcare, providing wearables that continuously monitor biomarkers and drugs in the blood.
Smartly, the company has chosen to target glucose first. This gives them an entry to the glucose monitoring device market that represents a growing proportion of the $50 billion diabetes care sector. Beyond this, Liom's combination of advanced spectral techniques and data analysis, alongside its "novel approach for technology miniaturisation", sets it up to expand into any number of healthcare branches and niches.
Early in 2024, Liom announced a breakthrough in its research, with its team achieving test results that showed only a 9% Mean Absolute Relative Difference (MARD) from the gold-standard measurement. It has also secured $15 million in additional funding which will support the conclusion of its first R&D phase.
Steph
Company Specialist at Welcome to the Jungle
Dec 2024
$25m
SERIES A
Jan 2024
$15m
CONVERTIBLE
Leo Grünstein
(Founder & CEO)Co-founder and Board Member at Caeli Nova, and Chairman at LG Capital. Former Co-founder and Board Member at MoneyPark, and also worked at McKinsey & Company as an Engagement Manager.